scholarly journals Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2359
Author(s):  
Liliana Montella ◽  
Lucia Altucci ◽  
Federica Sarno ◽  
Carlo Buonerba ◽  
Stefano De Simone ◽  
...  

Soft-tissue sarcomas are rare tumors characterized by pathogenetic, morphological, and clinical intrinsic variability. Median survival of patients with advanced tumors are usually chemo- and radio-resistant, and standard treatments yield low response rates and poor survival results. The identification of defined genomic alterations in sarcoma could represent the premise for targeted treatments. Summarizing, soft-tissue sarcomas can be differentiated into histotypes with reciprocal chromosomal translocations, with defined oncogenic mutations and complex karyotypes. If the latter are improbably approached with targeted treatments, many suggest that innovative therapies interfering with the identified fusion oncoproteins and altered pathways could be potentially resolutive. In most cases, the characteristic genetic signature is discouragingly defined as “undruggable”, which poses a challenge for the development of novel pharmacological approaches. In this review, a summary of genomic alterations recognized in most common soft-tissue sarcoma is reported together with current and future therapeutic opportunities.

2017 ◽  
Vol 41 (12) ◽  
pp. 2613-2618 ◽  
Author(s):  
Michael Parry ◽  
Scott Evans ◽  
Subin Sugath ◽  
Hazem Wafa ◽  
Lee Jeys ◽  
...  

2008 ◽  
Vol 13 (2) ◽  
pp. 57-64
Author(s):  
Kevin B. Jones ◽  
Peter C. Ferguson ◽  
Rita Kandel ◽  
Jay S. Wunder

2009 ◽  
Vol 89 (1) ◽  
pp. 235-247 ◽  
Author(s):  
Robert J. Kenney ◽  
Richard Cheney ◽  
Margaret A. Stull ◽  
William Kraybill

2015 ◽  
Vol 38 (3) ◽  
pp. 266-271 ◽  
Author(s):  
Hiroshi Urakawa ◽  
Satoshi Tsukushi ◽  
Eisuke Arai ◽  
Eiji Kozawa ◽  
Naohisa Futamura ◽  
...  

Sarcoma ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-15 ◽  
Author(s):  
Kirill I. Kirsanov ◽  
Ekaterina A. Lesovaya ◽  
Timur I. Fetisov ◽  
Beniamin Yu Bokhyan ◽  
Gennady A. Belitsky ◽  
...  

Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.


Sign in / Sign up

Export Citation Format

Share Document